| 22/04/24 | 07:00:10 | 22 Apr 2024 | | US and EU patents for innovative CellKeep™ slide |
| 08/04/24 | 07:00:09 | 8 Apr 2024 | | Parsortix HER2 assay showcased at AACR 2024 |
| 22/03/24 | 07:00:11 | 22 Mar 2024 | | Parsortix at European breast cancer conference |
| 22/01/24 | 07:00:11 | 22 Jan 2024 | | Potential utility in precision oncology |
| 10/01/24 | 12:57:47 | 10 Jan 2024 | | Standard form for notification of major holdings |
| 04/01/24 | 07:00:03 | 4 Jan 2024 | | Breakthrough clinical results |
| 02/01/24 | 07:00:05 | 2 Jan 2024 | | Contract announcement with Eisai Inc. |
| 11/12/23 | 07:00:15 | 11 Dec 2023 | | Broker Announcement |
| 11/12/23 | 07:00:11 | 11 Dec 2023 | | Parsortix unlocks opportunities for drug discovery |
| 05/12/23 | 07:00:14 | 5 Dec 2023 | | ANGLE launches Portrait+ CTC kit at SABCS |
| 09/11/23 | 07:00:19 | 9 Nov 2023 | | Launch of PD-L1 test to support cancer studies |
| 09/11/23 | 07:00:10 | 9 Nov 2023 | | Trading and business update |
| 25/10/23 | 07:00:14 | 25 Oct 2023 | | Supporting characterisation of CTCs in HNSCC |
| 03/10/23 | 07:00:09 | 3 Oct 2023 | | Parsortix outperforms standard for DTC harvest |
| 29/09/23 | 07:00:16 | 29 Sept 2023 | | Parsortix system showcased at ACTC conference |
| 07/09/23 | 07:00:04 | 7 Sept 2023 | | Interim Results for the period ended 30 June 2023 |
| 04/09/23 | 07:00:05 | 4 Sept 2023 | | ANGLE launch of Portrait Flex assay |
| 15/08/23 | 07:00:06 | 15 Aug 2023 | | ANGLE notice of interim results |
| 28/06/23 | 16:54:33 | 28 Jun 2023 | | Result of 2023 Annual General Meeting |
| 27/06/23 | 12:24:09 | 27 Jun 2023 | | Standard form for notification of major holdings |
| 05/06/23 | 07:00:09 | 5 Jun 2023 | | ANGLE announces senior management appointments |
| 25/05/23 | 07:00:08 | 25 May 2023 | | Pharma services contract with Artios Pharma |
| 22/05/23 | 07:00:05 | 22 May 2023 | | Board change - appointment of new Chairman |
| 21/04/23 | 12:04:09 | 21 Apr 2023 | | ANGLE presentation via Investor Meet Company |
| 21/04/23 | 07:00:03 | 21 Apr 2023 | | Results for the year ended 31 December 2022 |
| 19/04/23 | 07:00:04 | 19 Apr 2023 | | ANGLE announces partnership with BioView |
| 17/04/23 | 07:00:07 | 17 Apr 2023 | | ANGLE Parsortix poster presented at AACR 2023 |
| 13/04/23 | 07:00:05 | 13 Apr 2023 | | Pharma Services Contract with Crescendo Biologics |
| 03/04/23 | 07:00:17 | 3 Apr 2023 | | Notice of Preliminary Results and Webcast |
| 10/03/23 | 07:00:07 | 10 Mar 2023 | | Issue of LTIP Options and Share Options |
| 09/03/23 | 15:03:05 | 9 Mar 2023 | | Holding(s) in Company |
| 09/02/23 | 14:44:50 | 9 Feb 2023 | | Director/PDMR shareholding |
| 19/01/23 | 07:00:08 | 19 Jan 2023 | | Appointment of Non-Executive Director |
| 11/01/23 | 17:20:01 | 11 Jan 2023 | | Holding(s) in Company |
| 10/01/23 | 18:20:01 | 10 Jan 2023 | | Holding(s) in Company |
| 06/01/23 | 11:05:18 | 6 Jan 2023 | | Second Price Monitoring Extn |
| 06/01/23 | 11:00:13 | 6 Jan 2023 | | Price Monitoring Extension |
| 05/01/23 | 09:05:21 | 5 Jan 2023 | | Second Price Monitoring Extn |
| 05/01/23 | 09:00:21 | 5 Jan 2023 | | Price Monitoring Extension |
| 05/01/23 | 07:01:01 | 5 Jan 2023 | | Appointment of Non-Executive Director |
| 05/01/23 | 07:00:06 | 5 Jan 2023 | | Business Update |
| 12/12/22 | 07:00:04 | 12 Dec 2022 | | Two Parsortix posters presented at SABCS |
| 02/12/22 | 17:30:01 | 2 Dec 2022 | | Issue of Equity |
| 02/11/22 | 07:00:09 | 2 Nov 2022 | | Multiple downstream analysis techniques for CTCs |
| 01/11/22 | 16:41:31 | 1 Nov 2022 | | Second Price Monitoring Extn |
| 01/11/22 | 16:35:57 | 1 Nov 2022 | | Price Monitoring Extension |
| 24/10/22 | 07:00:10 | 24 Oct 2022 | | Parsortix poster presented at ISLB meeting |
| 21/10/22 | 18:15:01 | 21 Oct 2022 | | Issue of Equity |
| 18/10/22 | 07:00:06 | 18 Oct 2022 | | Streamlining of operations to increase cash runway |
| 17/10/22 | 14:23:14 | 17 Oct 2022 | | TR-1: Notification of major holdings |
